NASDAQ:CYAD CELYAD SA/ADR Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding CELYAD SA/ADR Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $9.76 -0.33 (-3.27 %) (As of 09/18/2020 12:00 AM ET) Add Compare Share Today's Range$9.75Now: $9.76▼$9.9550-Day Range$9.70MA: $10.06▼$10.5752-Week Range$4.10Now: $9.76▼$13.01Volume4,629 shsAverage Volume17,716 shsMarket Capitalization$136.07 millionP/E RatioN/ADividend YieldN/ABeta1.29 ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma. The company was formerly known as Cardio3 BioSciences SA and changed its name to Celyad SA in May 2015. Celyad SA was founded in 2004 and is based in Mont-Saint-Guibert, Belgium.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingCELYAD SA/ADR has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $28.50, CELYAD SA/ADR has a forecasted upside of 192.0% from its current price of $9.76.Amount of Analyst CoverageCELYAD SA/ADR has received no research coverage in the past 90 days. Previous Next 2.7 Community Rank Outperform VotesCELYAD SA/ADR has received 263 “outperform” votes. (Add your “outperform” vote.)Underperform VotesCELYAD SA/ADR has received 224 “underperform” votes. (Add your “underperform” vote.)Community SentimentCELYAD SA/ADR has received 54.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about CELYAD SA/ADR and other stocks. Vote “Outperform” if you believe CYAD will outperform the S&P 500 over the long term. Vote “Underperform” if you believe CYAD will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldCELYAD SA/ADR does not currently pay a dividend.Dividend GrowthCELYAD SA/ADR does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CELYAD SA/ADR insiders have not sold or bought any company stock.Percentage Held by InstitutionsOnly 6.10% of the stock of CELYAD SA/ADR is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for CELYAD SA/ADR are expected to grow in the coming year, from ($2.79) to ($2.16) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CELYAD SA/ADR is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CELYAD SA/ADR is -3.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCELYAD SA/ADR has a P/B Ratio of 2.66. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.37 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYAD Previous Symbol CUSIPN/A CIK1637890 Webwww.celyad.com Phone321-039-4100Debt Debt-to-Equity Ratio0.08 Current Ratio2.73 Quick Ratio3.59Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10,000.00 Price / Sales13,607.39 Cash FlowN/A Price / Cash FlowN/A Book Value$3.67 per share Price / Book2.66Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous EmployeesN/A Outstanding Shares13,942,000Market Cap$136.07 million Next Earnings DateN/A OptionableNot Optionable $9.76 -0.33 (-3.27 %) (As of 09/18/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive CYAD News and Ratings via Email Sign-up to receive the latest news and ratings for CYAD and its competitors with MarketBeat's FREE daily newsletter. CELYAD SA/ADR (NASDAQ:CYAD) Frequently Asked Questions How has CELYAD SA/ADR's stock been impacted by COVID-19? CELYAD SA/ADR's stock was trading at $7.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CYAD shares have increased by 24.3% and is now trading at $9.76. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of CELYAD SA/ADR? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CELYAD SA/ADR in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for CELYAD SA/ADR. What price target have analysts set for CYAD? 3 Wall Street analysts have issued twelve-month price targets for CELYAD SA/ADR's shares. Their forecasts range from $20.00 to $37.00. On average, they anticipate CELYAD SA/ADR's stock price to reach $28.50 in the next year. This suggests a possible upside of 192.0% from the stock's current price. View analysts' price targets for CELYAD SA/ADR. Are investors shorting CELYAD SA/ADR? CELYAD SA/ADR saw a decrease in short interest in August. As of August 31st, there was short interest totaling 6,100 shares, a decrease of 17.6% from the August 15th total of 7,400 shares. Based on an average trading volume of 14,500 shares, the days-to-cover ratio is presently 0.4 days. View CELYAD SA/ADR's Short Interest. Who are some of CELYAD SA/ADR's key competitors? Some companies that are related to CELYAD SA/ADR include Eagle Pharmaceuticals (EGRX), Ardelyx (ARDX), Vanda Pharmaceuticals (VNDA), Ocular Therapeutix (OCUL), Atreca (BCEL), Neoleukin Therapeutics (NLTX), Mirum Pharmaceuticals (MIRM), Crinetics Pharmaceuticals (CRNX), Cue Biopharma (CUE), Northwest Biotherapeutics (NWBO), Axovant Sciences (AXON), Viking Therapeutics (VKTX), Odonate Therapeutics (ODT), Homology Medicines (FIXX) and IVERIC bio (ISEE). View all competitors. What other stocks do shareholders of CELYAD SA/ADR own? Based on aggregate information from My MarketBeat watchlists, some companies that other CELYAD SA/ADR investors own include GALAPAGOS NV/S (GLPG), Cellectis (CLLS), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), Chromadex (CDXC), SCYNEXIS (SCYX), bluebird bio (BLUE), Ra Pharmaceuticals (RARX), AbbVie (ABBV) and argenx (ARGX). Who are CELYAD SA/ADR's key executives? CELYAD SA/ADR's management team includes the following people: Mr. Michel E. Lussier, Co-Founder & Chairman (Age 63)Mr. Filippo Joseph Petti, CEO & Interim CFODr. Jean-Pierre Latere, Chief Operating Officer (Age 44)Nicolas Van Hoecke, Director of Investor Relations & CommunicationsMr. Philippe Dechamps, Chief Legal Officer (Age 49) When did CELYAD SA/ADR IPO? (CYAD) raised $99 million in an IPO on Friday, June 19th 2015. The company issued 1,400,000 shares at a price of $70.98 per share. UBS Investment Bank and Piper Jaffray served as the underwriters for the IPO and Petercam Bryan, Garnier, LifeSci Capital and Lake Street Capital Markets were co-managers. What is CELYAD SA/ADR's stock symbol? CELYAD SA/ADR trades on the NASDAQ under the ticker symbol "CYAD." Who are CELYAD SA/ADR's major shareholders? CELYAD SA/ADR's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Victory Capital Management Inc. (5.63%). Which major investors are selling CELYAD SA/ADR stock? CYAD stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc.. How do I buy shares of CELYAD SA/ADR? Shares of CYAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is CELYAD SA/ADR's stock price today? One share of CYAD stock can currently be purchased for approximately $9.76. How big of a company is CELYAD SA/ADR? CELYAD SA/ADR has a market capitalization of $136.07 million and generates $10,000.00 in revenue each year. The company earns $-32,070,000.00 in net income (profit) each year or ($2.57) on an earnings per share basis. What is CELYAD SA/ADR's official website? The official website for CELYAD SA/ADR is www.celyad.com. How can I contact CELYAD SA/ADR? CELYAD SA/ADR's mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company can be reached via phone at 321-039-4100. This page was last updated on 9/21/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
